Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma

BACKGROUND: RAS effector signaling pathways such as PI3K/mTOR and ERK are frequently dysregulated in glioblastoma. While small molecule targeted therapies against these pathways have appeared promising in preclinical studies, they have been disappointing in clinical trials due to toxicity and de nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreck, Karisa C, Allen, Amy N, Wang, Jiawan, Pratilas, Christine A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668446/
https://www.ncbi.nlm.nih.gov/pubmed/33235998
http://dx.doi.org/10.1093/noajnl/vdaa138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668446/
https://www.ncbi.nlm.nih.gov/pubmed/33235998
http://dx.doi.org/10.1093/noajnl/vdaa138

Ejemplares similares